Equity · Healthcare
BCRX
NASDAQBioCryst Pharmaceuticals (BCRX)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 2.0B USD
- Revenue, year to Dec 2025
- 874.8M USD
- EPS, diluted, year to Dec 2025
- 1.21 USD
- 52-week range
- 6.24 USD – 11.01 USD
- Avg volume
- 473.4K
as of Nov 9, 2026
Have BioCryst Pharmaceuticals (BCRX) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, no BioCryst Pharmaceuticals insider bought or sold shares on the open market; all 5 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 11 Nov 2026, newest Form 4 filing 31 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 31 Aug 2026 | Frank StevenDirector | Award | 1,288 | 12K USD |
| 31 Aug 2026 | McKee Amy EDirector | Award | 644 | 6K USD |
| 31 Aug 2026 | MILANO VINCENTDirector | Award | 1,159 | 11K USD |
| 31 Aug 2026 | Milne Jill C.Director | Award | 1,288 | 12K USD |
| 31 Aug 2026 | Stonehouse Jon PDirector | Award | 644 | 6K USD |
Which funds hold BioCryst Pharmaceuticals (BCRX)?
1 of the 45 institutional funds we track reported a BioCryst Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 20.4M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 2,448,598 | 20.4M USD | −6.0% |
Have members of Congress traded BioCryst Pharmaceuticals (BCRX)?
The most recent congressional trade disclosed in BioCryst Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 13 Nov 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 13 Nov 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 32 days |
| 16 Oct 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 26 days |
| 15 Sep 2023 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 30 days |
| 11 Aug 2022 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 36 days |
What has been filed or recorded for BioCryst Pharmaceuticals (BCRX)?
The filings we hold for BioCryst Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 18,843 shares | 152K USD notional · 0.007% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.14 USD | |
| 30 Sep 2026 | Financials | Total assets | 591.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −397.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.30 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −2.98 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.21 USD | |
| 31 Dec 2025 | Financials | Revenue | 874.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 263.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.21 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.06 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.02 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.00 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.43 USD |
What do people ask about BioCryst Pharmaceuticals (BCRX)?
What is BioCryst Pharmaceuticals’ market cap?2.0B
BioCryst Pharmaceuticals is worth 2.0B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is BioCryst Pharmaceuticals’ revenue?874.8M
BioCryst Pharmaceuticals reported revenue of 874.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have BioCryst Pharmaceuticals insiders bought or sold shares recently?5 filings
In the 90 days to 11 Nov 2026, no BioCryst Pharmaceuticals insider bought or sold shares on the open market; all 5 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own BioCryst Pharmaceuticals?1 of 45
1 of the 45 funds we track reported a BioCryst Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded BioCryst Pharmaceuticals?4 trades
Yes. 4 trades in BioCryst Pharmaceuticals appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 13 Nov 2025, filed 15 Dec 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did BioCryst Pharmaceuticals last report earnings?0.14
BioCryst Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.14 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain; Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings